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Background: Tyrosine kinase inhibitors (TKIs) have improved response rates in some patients 
with non-small cell lung cancer (NSCLC), and testing for EGFR mutation and ALK translocation 
is recommended for all patients with advanced lung adenocarcinoma. The frequency of driver 
mutations in elderly and very elderly patients has not been described.
Patients and methods: We reviewed EGFR and ALK in patients over the age of 70 years 
diagnosed and treated at our center in 2015 (subgroups: 70–74, 75–79 and .80 years). We then 
assessed a second cohort, including all patients with lung cancer over the age of 80 years 
diagnosed in 2014. We also analyzed smoking history, treatment and response.
Results: In the 2015 cohort of 179 patients, 16 were 80 years or older at diagnosis. Six of eight 
(75%) octogenarians with non-squamous NSCLC were EGFR or ALK positive. The 2014 cohort 
confirmed the high rate of driver alterations in octogenarians. Of 334 patients, 32 were 80 years 
or older and, of these, 10 had non-squamous histology and were tested for driver alterations 
(four of 10 [40%] EGFR or ALK positive). Rates of genetic drivers were somewhat lower in 
patients with non-squamous NSCLC aged 70–74 years (27.0%) and 75–79 years (26.7%). When 
treated with a TKI, octogenarians had high response rates and progression-free survival. Most 
octogenarians with lung adenocarcinoma were never smokers, with an inverse correlation of 
pack-years smoked to age at diagnosis.
Conclusion: Very elderly patients with non-squamous NSCLC show high rates of driver 
alterations in EGFR and ALK. This, often frail and comorbid, population may not be fit for 
treatment with cytotoxic chemotherapy and may benefit from targeted treatments. Testing for 
EGFR and ALK alterations should not be restricted to younger patients. The biology of lung 
cancer in the very elderly may differ from that of moderately elderly patients, as longevity may 
select for individuals more resistant to, or with little exposure to, environmental carcinogens.
Keywords: molecular biology, pathology, elderly, very elderly, NSCLC, biomarker, targeted 
therapy
Introduction
Tyrosine kinase inhibitors (TKIs) targeting EGFR mutations and EML4–ALK 
translocations improve response rates and prolong survival in a subset of patients with 
advanced non-small cell lung cancer (NSCLC). Previous studies have linked EGFR 
mutation to younger age, female gender and a never or light smoking history.10,28,29 
ALK translocation has also been shown to occur in younger patients and those with 
a little exposure to cigarette smoke. As a result, patients included in trials of targeted 
TKIs have often been relatively young, with an average age of 61 years in the Lux 
Lung 3 trial1 and 53 years in the Profile 1014 trial.2 Some trials of EGFR TKIs excluded 
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patients over the age of 75 years.3,4 In contrast, the average 
lung cancer patient in Germany is elderly, aged almost 
70 years at the time of first diagnosis.5
Current guidelines6,7 recommend testing all patients 
with lung adenocarcinoma for EGFR mutation and ALK 
translocation, regardless of age or other clinical factors and 
recommend treating patients with these molecular alterations 
with a first-line EGFR or ALK TKI. However, barriers to uni-
versal testing continue to exist in many health care settings, 
and not all patients who may benefit from TKI therapy are 
tested for molecular drivers. In particular, use of EGFR and 
ALK testing appears to be quite low in elderly patients. 
A recent analysis of 1,358 patients with NSCLC documented 
in the Surveillance, Epidemiology, and End Results (SEER) 
Program of the National Cancer Institute database showed a 
marked inverse correlation between the frequency of EGFR 
testing and age, with testing in only 13.7% of adenocarcinoma 
patients over the age of 80 years, compared with testing 
in 55.3% of patients under 50 years, 22.8% of those aged 
50–59 years and 22.9% of those aged 60–69 years.8
Because of the good tolerability profile of TKIs, elderly 
patients – including frail elderly patients who may be poor 
candidates for chemotherapy – may benefit from treatment 
with EGFR or ALK TKIs if the relevant molecular drivers 
are identified. However, there are currently little data as to 
the rate of EGFR and ALK alterations and response to TKIs 
in elderly patients with NSCLC.
In this analysis, we sought to describe rates of EGFR muta-
tion and ALK translocation in elderly patients with NSCLC 
in a tertiary-care university hospital setting in Germany.
Patients and methods
study design and objectives
The primary objective of this retrospective study was to deter-
mine the incidence of EGFR mutation and ALK translocation 
in very elderly patients, defined as those 80 years of age or older 
at the time of first diagnosis. Secondary objectives included 
comparing the molecular biology of tumors in very elderly 
patients with younger seniors aged 70–74 and 75–79 years; 
describing targeted treatment administered and response to 
targeted treatment in very elderly patients with NSCLC and 
examining smoking behavior in very elderly patients. The 
primary objective was examined in two independent patient 
cohorts. Approval for this retrospective analysis was obtained 
from the responsible ethics committee (Ethics Committee 
of the University of Munich). Due to the retrospective and 
anonymized nature of the data, individual patient consent was 
not required (Ethics Committee Decision number 476-16 UE). 
The study was conducted according to the Declaration of 
Helsinki, Good Clinical Practice guidelines and local ethical, 
legal and confidentiality of data requirements.
Patient cohorts
The first cohort included all patients with lung cancer over 
the age of 70 years diagnosed and treated in 2015 at the 
university hospital affiliated with the Ludwig-Maximilians 
University of Munich. The university hospital is a member 
of the Munich Lung Cancer Center. We reviewed the charts 
and electronic patient records and assessed the frequency and 
result of EGFR and ALK testing. To confirm the primary find-
ing of the study and to increase the number of patients over 
the age of 80 years available for exploratory analyses, we then 
examined a second cohort of octogenarians. For this second 
cohort, we identified all patients with lung cancer diagnosed 
in 2014 seen at the university hospital at any time following 
first diagnosis until October 2016 and reviewed the charts of 
those over 80 years of age at the time of first diagnosis.
egFr and alK testing
Screening for ALK alterations was performed by immuno-
histochemistry (clone D5F3, ready-to-use test kit for Ventana 
platform according to the manufacturer’s instructions; Ventana 
Medical Systems, Inc., Oro Valley, AZ, USA). Positive results 
of ALK immunohistochemistry were confirmed by fluores-
cence in situ hybridization (Spec ALK/EML4 TriCheck 
probe, Zytovision; Zytomed GmbH, Berlin, Germany) with 
concordant results. Mutational analysis of exons 18–20 of 
EGFR gene was performed by Sanger sequencing following 
manual microdissection of tumor areas.
statistical analysis
Data sets were anonymized prior to analysis. Statistical 
analyses were performed using GraphPad QuickCalcs 
Software. The Chi-square test was applied to compare cat-
egorical data. p-values were two tailed, and values under 
0.05 were considered significant. Linear regression was 
used to describe the association between age and smoking. 
Subgroup analyses of elderly patients aged 70–74, 75–79 
and .80 years in cohort 1 were preplanned. Cohorts 1 and 2 
were pooled for an exploratory descriptive analysis of 
smoking history, treatment with TKI and response to treat-
ment in octogenarians with driver alterations.
Results
Out of 179 patients diagnosed and treated at our center in 
2015 (cohort 1), 16 (8.9%) were 80 years or older at the time 
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of first diagnosis, 26 were 75–79 (14.5%) years of age and 
33 (18.4%) were 70–74 years of age. Of the 16 octogenar-
ians in this cohort, 8 (50%) had non-squamous histology and 
were tested for EGFR and ALK. Among these very elderly 
patients, three patients were found to have EML4–ALK 
translocations and three patients were found to have EGFR 
mutation (one Del19, one L858R, one rare EGFR mutation in 
exon 19). This represents a 75% frequency of treatable driver 
mutations in octogenarians with non-squamous NSCLC. 
The frequency of these driver alterations was then assessed 
in a second cohort of octogenarians. Out of 335 patients 
diagnosed in 2014 and seen at our center following their 
diagnosis (cohort 2), 32 (9.6%) were 80 years or older at 
the time of first diagnosis and 10 (31%) of these octogenar-
ians had non-squamous NSCLC and were tested for EGFR 
and ALK. One patient was found to have an EML4–ALK 
translocation, and three patients were found to have an 
EGFR mutation, representing a 40% frequency of treatable 
driver alterations in octogenarians in this cohort; the data are 
summarized in Table 1.
The incidence of genetic drivers in patients with non-
squamous NSCLC aged 70–74 and 75–79 years in cohort 1 
was 27.0% and 26.7%, respectively. In comparison, the inci-
dence of molecular driver alterations in patients over the age of 
80 years was significantly higher, both in cohort 1 (p=0.0022) 
and when considering both cohorts together (p=0.0064). 
A pooled analysis of all patients aged 70–79 years vs those 
over 80 years confirmed the significantly higher incidence 
of EGFR/ALK alterations in octogenarians compared with 
younger seniors aged 70–79 years (p=0.039).
Interestingly, in each cohort, the single most elderly 
patient had a treatable driver mutation; in cohort 1, this was 
a 91-year-old woman with EML4–ALK translocation and in 
cohort 2 a 95-year-old woman with EGFR mutation. Among 
the octogenarians in cohort 1 and cohort 2, there was a trend 
toward more advanced age in the subgroup with treatable 
driver mutations (85.3 years in cohort 1 and 86.2 years in 
cohort 2) than in the subgroup without a treatable driver 
mutation (84 years in cohort 1 and 83.4 years in cohort 2).
smoking
An analysis of the smoking history of elderly patients with 
lung cancer showed that both active smoking and previous 
smoking was more prevalent in younger seniors than in 
octogenarians. In the 70–74-year-old subgroup, 30% were 
active smokers at the time of first diagnosis and only 9% had 
never smoked, whereas only 8% of octogenarians smoked 
actively at the time of first diagnosis and 19% were never 
smokers. The average pack-years (PY) smoked decreased 
with increasing subgroup age (Figure 1), with an average 
of 40.3 PY in 70–74 year olds, 34.3 PY in 75–79 year olds 
and 27.5 PY in those over the age of 80 years; the data are 
summarized in Table 2. The majority of octogenarians with 
driver alterations were never smokers, and the average 
smoking burden in this group was 4.4 PY (Table 3).
There was a strong trend toward longer survival for 
octogenarian nonsmokers compared with octogenarian ex-
smokers/smokers (mean overall survival 21.2 vs 12.2 months; 
p=0.0770). We did not find a survival difference between 
smokers and nonsmokers within either the subgroup with 
driver alterations or the subgroup with no driver alteration. 
The overall survival of heavier smokers (.50 PY) did not 
differ significantly from that of lighter smokers (,50 PY). 
Approximately 10% of lung cancer patients aged 70–80 years 
Table 1 characteristics of elderly lung cancer patients in cohort 1 and cohort 2
Characteristics Elderly 
patients 
(.70 years)
Cohort 1 Cohort 2
Patients 70–74 years 
of age at the time 
of first diagnosis
Patients 75–79 years 
of age at the time 
of first diagnosis
Patients 80 years of 
age or older at the 
time of first diagnosis
Patients 80 years of 
age or older at the 
time of first diagnosis
Total, n (%) 75 (100) 33 (44) 26 (35) 16 (21) 32 (100)
gender, n (%)
Male 48 (64) 18 (55) 19 (73) 11 (69) 14 (44)
Female 27 (36) 15 (45) 7 (27) 5 (31) 18 (56)
Mean age at first 
diagnosis (years)
76.3 71.9 76.7 84.4 82.9
Patients with non-squamous 
nsclc tested for egFr 
and alK, n
45 22 15 8 10
egFr positive, n (%) 13 (29) 6 (27) 4 (27) 3 (38) 3 (30)
alK positive, n (%) 3 (6) 0 0 3 (38) 1 (10)
Abbreviation: nsclc, non-small cell lung cancer.
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were very heavy smokers with over 80 PY smoking history. 
There were no very heavy smokers (.80 PY) in the octo-
genarian cohort.
Treatment with TKis
In our very elderly subgroup, eight out of the 10 octogenar-
ians with driver alterations were treated with a targeted TKI. 
The remaining two underwent a surgical resection without 
systemic therapy. Seven patients received a TKI as first-line 
treatment, and one patient was initially treated with four 
cycles of pemetrexed monotherapy before being switched to 
crizotinib. Seven of eight patients treated with a TKI benefited 
both clinically and in terms of Response Evaluation Criteria 
in Solid Tumors response, with an average time to progres-
sion of 13.6 months (Figure 2). One patient discontinued 
crizotinib treatment after 3 weeks and requested a transfer to 
hospice care. This patient could not be assessed for response. 
Two patients progressing on EGFR TKIs were found to have 
T790M mutations and were switched to osimertinib with good 
treatment effect. Overall survival of octogenarians with driver 
alterations treated with a TKI was 75% at 12 months and 57% 
at 24 months. Table 3 summarizes the treatments and response 
of the octogenarian subgroup with driver mutations.
Discussion
Clinically relevant molecular alterations in NSCLC are 
believed to be more prevalent in younger patient popula-
tions. This study found a clinically relevant incidence of 
EGFR mutation and ALK translocation in very elderly, 
octogenarian patients with non-squamous NSCLC. The 
incidence of driver alterations was higher in very elderly 
patients than in younger seniors aged 70–79 years. To our 
knowledge, this is the first study to report on the incidence 
of these genetic drivers in very elderly patients with lung 
cancer and is also the first study to compare the incidence of 
these genetic drivers in very elderly patients (.80 years) to 
other elderly subgroups. Previous data from a large German 
cohort of 4,196 adults (average age 66 years) describe EGFR 
mutations in 10.3% of patients, with higher incidence in 
females (16.7%), never smokers (26.2%) and patients with 
adenocarcinoma (13.1%).9
At first glance, the finding of a high incidence of molecu-
lar driver alterations in octogenarians seems to contradict 
well-established findings in the biology of lung cancer: EGFR 
mutation and ALK translocation are generally associated 
with a set of clinical features including a limited smoking 
history and a younger than average age at the time of tumor 
diagnosis. The association of these driver alterations with 
younger patients has been confirmed by many groups, 

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Figure 1 smoking history of elderly patients with lung cancer.
Notes: Very elderly patients with lung cancer reported less smoking than did 
younger seniors with lung cancer. linear regression was used to describe the 
association between age and smoking. slope is -1.4±0.55 (95% ci -2.5 to -0.32, 
p=0.0120 for nonzero slope).
Abbreviation: PY, pack-years.
Table 2 smoking and histology data for cohort 1 and cohort 2 (pooled)
Characteristics All elderly 
patients 
(.70 years)
Patients 70–74 years 
of age at the time 
of first diagnosis
Patients 75–79 years 
of age at the time 
of first diagnosis
Patients 80 years of 
age or older at the 
time of first diagnosis
smoking history, n 107 33 26 48
never smoker 16 3 (9%) 4 (15%) 9 (19%)
ex-smoker 41 14 (42%) 11 (42%) 16 (33%)
active smoker 18 10 (30%) 4 (15%) 4 (8%)
Unknown 32 6 (18%) 7 (27%) 19 (40%)
average PY 32.2 40.3 34.3 27.5
histology, n (%)
adenocarcinoma 50 19 (57) 13 (50) 18 (38)
Other non-squamous nsclc 9 3 (9) 3 (12) 3 (6)
squamous cell carcinoma 29 4 (12) 8 (31) 17 (35)
sclc 13 6 (18) 0 7 (15)
Others 6 1 (3) 2 (8) 3 (6)
Abbreviations: nsclc, non-small cell lung cancer; PY, pack-years; sclc, small cell lung cancer.
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including our own.10 However, when the factors leading 
to the development of lung cancer and the decreased life 
expectancy of smokers are considered, the finding of driver 
mutations in the very elderly does not seem counterintui-
tive. It could be that those seniors who survive to develop 
lung cancer at a very advanced age have had relatively little 
lifelong exposure to carcinogenic tobacco smoke or are 
resistant to its effects.
Although the incidence of lung cancer increases with 
increasing age and elderly patients make up the bulk of 
patients with lung cancer, younger seniors predominate and 
very elderly patients are a small subgroup. In the current 
study, fewer than 10% of lung cancer patients were diagnosed 
at or over the age of 80 years. Epidemiological data show 
that, rather than steadily increasing with increasing age, both 
lung cancer incidence and cancer mortality peak in elderly 
patients and then decrease in very elderly patient cohorts.11 
Data from the SEER database describe lower incidence of 
lung cancer in those 80–84 years of age and 85+ years than 
in those aged 75–79 years.12 In addition, an analysis of census 
data from the USA showed that while 40% of deaths in those 
aged 50–69 years were due to cancer, cancer accounted for 
only 4% of all deaths in patients over the age of 100 years.13 
This may be in part due to the decreased life expectancy of 
smokers, who are less likely to live to the age of 80 years 
as nonsmokers.14 A large study including over one million 
British women found that, compared with only 22% of never 
smokers, 53% of smokers die before reaching 80 years of 
age.15 A study of Italian centenarians showed that 83.8% of 
those who reach the age of 100 years have never smoked.16 
German data on smoking behavior at various ages17 show 
that smoking is most common among young adults aged 
18–29 years, with 40% of women and 47% of men smoking 
daily or on occasion. Heavy smoking (20 or more cigarettes 
a day) is most common among 30–44 year olds.17 Elderly 
individuals aged 65–79 years smoke infrequently in Germany 
(8.5% of men and 16.8% of women), and only rarely smoke 
heavily (1.5% of elderly women and 2.4% of elderly men).17 
However, in addition to lack of smoking, genetic factors 
may also play a role in the decreased lung cancer incidence 
in the very elderly. In a study examining the frequency of 
chromosomal aberrations in younger and older patients, 
Erceg et al18 found more aberrations in patients over the 
age of 65 years than in those under the age of 65 years but 
fewer chromosomal aberrations in the very elderly (over 
the age of 80 years) than in younger seniors. There seem 
to be protective genetic factors present in those who reach 
extremely old age.
As most investigations to date have considered all elderly 
patients as a single group, generally defined as over the age of 
65 years or over the age of 70 years, rather than further strati-
fying based on age, differences in the biology of lung cancer 
in the very elderly may be overlooked. In contrast, geriatri-
cians assessing medical interventions in elderly populations 
often age stratify their patients as “young old,” “middle old” 
and “old old.”19,20 The current study and previous work in 
other solid tumours21 support the use of an age-stratified 
approach to the biology of cancer in the elderly as tumors 
which occur in the very elderly appear to differ significantly 
from those which develop in elderly patients 10 or 20 years 
younger. There may be at least three biologically relevant 
age groups in terms of the molecular biology of lung cancer. 
Lung cancer in the very young seems to arise relatively inde-
pendent of smoking history and displays a high incidence 
of molecular driver alterations. Lung cancer incidence is 
highest in middle age to young/mid-seniors and occurs pre-
dominantly in smokers or ex-smokers in these age groups. 
In the very elderly, lung cancer incidence decreases and a 
relevant proportion of those cases which do occur appear to 
be linked to molecular driver alterations. The current study 
found that octogenarians with lung adenocarcinoma are often 
never smokers. In addition, despite having had more life 
years in which to smoke, the average number of PY smoked 
by very elderly patients with lung cancer was lower than the 
amount smoked by younger seniors, suggesting that perhaps 
those who smoke most develop tumors earlier than those 
who have smoked less.
It is possible that the smoking history of patients seen at 
our university center is not perfectly representative of the 
smoking history of all patients with lung cancer in Germany. 
There may be an unconscious bias among primary care 
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physicians to preferentially refer patients to a university 
center based on factors such as higher socioeconomic status, 
good clinical condition and limited comorbidity, all of which 
may be associated with a lower smoking burden. This might 
lead to an overestimation of mutation prevalence in our 
study population. In addition to being a predisposing factor 
for EGFR and ALK wild-type tumor biology, smoking has 
been previously described as a negative prognostic factor in 
lung cancer.22 In the current study, octogenarian nonsmokers 
showed a strong trend to longer overall survival compared 
with former and current smokers; however, the subgroup of 
octogenarian nonsmokers with wild-type tumor biology was 
too small to draw conclusions about the independent impact 
of smoking, tumor biology and treatment on survival.
We are aware of only one other publication examining 
the rate of EGFR mutations in very elderly patients and no 
analyses examining ALK in this age group. Nishii et al23 
previously examined the rate of EGFR mutations in elderly 
Japanese patients with surgically resected lung cancer and 
found lower rates of EGFR mutation in those over the age 
of 80 years compared with younger patients. This group did 
not compare moderately elderly to very elderly patients. 
Interestingly, in the Nishii analysis, the rate of smoking 
in the elderly patient subgroup was significantly higher, at 
79.3%, than in the younger subgroup. As both tumor biology 
and smoking behavior differ between Japanese and German 
patient cohorts, these data are not directly comparable.
The current study found high rates of response and 
clinical benefit from TKIs in very elderly patients with 
molecular driver alterations treated with an appropriate 
EGFR or ALK TKI. Previous studies have reported that 
very elderly patients who are biologically fit may tolerate 
many of the treatment modalities offered to younger patients, 
including surgical resection and chemotherapy.24 However, 
some very elderly patients with advanced disease decline 
chemotherapy.25 Such patients may benefit from treatment 
with a TKI if a treatable driver alteration is identified.26 
The relatively high incidence of driver alterations in very 
elderly patients identified in the current study is clinically 
relevant and should motivate clinicians to biopsy and offer 
molecular testing to patients in this age group. Ayyappan 
et al27 previously described diagnostic decision making in 
very elderly patients aged 80 years or older at the time of 
lung cancer diagnosis. In their cohort from Rochester, New 
York, 18–23% of patients were over the age of 80 years at the 
time of diagnosis, and one-third of these patients declined, 
either alone or through family members, to have the diag-
nosis of lung cancer confirmed by a biopsy. The assumption 
that elderly patients will have low rates of driver mutations 
may contribute to the relatively low rate of testing for these 
alterations in very elderly patients in some settings. While 
some patients may still choose not to undergo a biopsy, 
very elderly patients should be informed about alternatives 
to chemotherapy and the possibility of finding molecular 
drivers before making this decision.
Conclusion
In this study, very elderly patients with non-squamous 
NSCLC were found to have relatively high rates of EGFR-
mutation and ALK-translocation. This finding is both 
clinically and biologically relevant. Although some physi-
ologically fit elderly patients benefit from chemotherapy, 
TKIs may also benefit frail or comorbid elderly patients 
who are not candidates for chemotherapy. As recommended 
by European6 and American7 guidelines, testing for these 
genetic alterations should not be restricted to younger 
patients. Biologically, the presence of a high rate of driver 
alterations in patients with lung cancer over the age of 
80 years suggests that the biology of lung cancer in various 
age cohorts and subgroups of elderly patients varies. The 
biology of tumors in the very elderly may differ from that of 
tumors in middle-aged patients and younger seniors. Very 
elderly patients may be less likely to have been heavily 
exposed to environmental carcinogens such as tobacco 
smoke or may have genetic factors which lessen the effect 
of such exposure. Studying the biology of carcinogenesis in 
very elderly patients may provide insights into factors which 
predispose to and protect against tumor development.
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